Tune Therapeutics
Jason Dean has worked in the field of bioinformatics for over 18 years. Jason began their career as a Graduate Student Researcher at UCLA in 2003. In 2010, they moved to Amgen as a Postdoctoral Research Fellow. In 2011, they were hired as a Senior Scientist - Expression at Merck Research Labs. Jason then moved to Matrix Genetics in 2013 as a Senior Research Scientist. In 2017, they joined Bellwether Bio as a Senior Scientific Programmer. In 2019, they were hired as a Senior Bioinformatics Scientist at Guardant Health. In 2020, they became a Principal Data Scientist at Shape Therapeutics Inc. and most recently, in 2022, they were appointed as the Head of Bioinformatics at Tune Therapeutics.
Jason Dean received a Bachelor of Science in Chemical Engineering from the Georgia Institute of Technology in 2003. Jason then went on to receive a PhD in Chemical Engineering from the University of California, Los Angeles in 2009.
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.